<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="2" ids="2948">Azathioprine</z:chebi> (Aza) is a widely used immunosuppressive drug in multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> (MS) treatment </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, the incidence of secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (sMDS) associated with a poor prognosis was found to be elevated in patients treated with Aza for non-malign disorders </plain></SENT>
<SENT sid="2" pm="."><plain>Three hundred and seventeen MS patients were retrospectively analysed and complete blood counts were examined for those exposed to Aza </plain></SENT>
<SENT sid="3" pm="."><plain>We identified one case of sMDS (cumulative dose 627 g) in a young patient and two further <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (cumulative doses 27 g and 54 g) in the <z:chebi fb="0" ids="52899">Aza group</z:chebi> (n = 81; 3.7%) </plain></SENT>
<SENT sid="4" pm="."><plain>In the non-Aza (n = 236) group, five <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (2.1%, P = 0.419) were identified </plain></SENT>
<SENT sid="5" pm="."><plain>Including our patient, four cases of sMDS after long-term Aza therapy in MS have been reported so far </plain></SENT>
<SENT sid="6" pm="."><plain>Cases suggest a time- and dose-dependent risk of sMDS in long-term therapy of MS with Aza </plain></SENT>
<SENT sid="7" pm="."><plain>Long-term Aza therapy needs careful monitoring </plain></SENT>
</text></document>